Skip to main content
Erschienen in: CNS Drugs 4/2010

01.04.2010 | Review Article

Childhood Medulloblastoma

Current Status of Biology and Treatment

verfasst von: Dr Laura J. Klesse, Daniel C. Bowers

Erschienen in: CNS Drugs | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Medulloblastoma, a primitive neuro-ectodermal tumour that arises in the posterior fossa, is the most common malignant brain tumour occurring in childhood. Over the past half century, the long-term survival for children with medulloblastoma has improved remarkably from a certain fatal diagnosis to a cancer that is often curable. Although overall survival for children with non-disseminated and non-anaplastic medulloblastoma can approach 80%, the current multidisciplinary therapeutic approach is not without long-term sequelae. Chemotherapy has improved the long-term survival and allowed for reductions in the amount of radiation given, thereby reducing some of the long-term toxicities. In this review, we describe the current understanding of the basic biology of medulloblastoma and report on the current active chemotherapeutic agents utilized in medulloblastoma therapy. Ultimately, our understanding of the basic biology of medulloblastoma may lead to further advances in therapy by providing targets that are more specific and potentially less toxic.
Literatur
1.
Zurück zum Zitat CBTRUS. Statistical report: primary brain tumors in the United States, 2005–2006 [online]. Hinsdale (IL): Central Brain Tumor Registry of United States, 2009. Available from URL: http://www.cbtrus.org [Accessed 2010 Jan 26] CBTRUS. Statistical report: primary brain tumors in the United States, 2005–2006 [online]. Hinsdale (IL): Central Brain Tumor Registry of United States, 2009. Available from URL: http://​www.​cbtrus.​org [Accessed 2010 Jan 26]
2.
Zurück zum Zitat Chan AW, Tarbell NJ, Black PM, et al. Adult medullo-blastoma: prognostic factors and patterns of relapse. Neurosurgery 2000 Sep; 47(3): 623–31; discussion 31-2PubMed Chan AW, Tarbell NJ, Black PM, et al. Adult medullo-blastoma: prognostic factors and patterns of relapse. Neurosurgery 2000 Sep; 47(3): 623–31; discussion 31-2PubMed
3.
Zurück zum Zitat Halperin EC, Friedman HS. Is there a correlation between duration of presenting symptoms and stage of medullo-blastoma at the time of diagnosis? Cancer 1996 Aug 15; 78(4): 874–80PubMedCrossRef Halperin EC, Friedman HS. Is there a correlation between duration of presenting symptoms and stage of medullo-blastoma at the time of diagnosis? Cancer 1996 Aug 15; 78(4): 874–80PubMedCrossRef
4.
Zurück zum Zitat Coffin CM, Braun JT, Wick MR, et al. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990 Mar; 3(2): 164–70PubMed Coffin CM, Braun JT, Wick MR, et al. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990 Mar; 3(2): 164–70PubMed
5.
Zurück zum Zitat Burger PC, Grahmann FC, Bliestle A, et al. Differentiation in the medulloblastoma: a histological and immunohistochemical study. Acta Neuropathol 1987; 73(2): 115–23PubMedCrossRef Burger PC, Grahmann FC, Bliestle A, et al. Differentiation in the medulloblastoma: a histological and immunohistochemical study. Acta Neuropathol 1987; 73(2): 115–23PubMedCrossRef
6.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97–109PubMedCrossRef Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97–109PubMedCrossRef
7.
Zurück zum Zitat Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003 Jul; 13(3): 376–85PubMedCrossRef Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003 Jul; 13(3): 376–85PubMedCrossRef
8.
Zurück zum Zitat Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002 Jan 15; 94(2): 552–60PubMedCrossRef Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002 Jan 15; 94(2): 552–60PubMedCrossRef
9.
Zurück zum Zitat Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004 Mar 15; 22(6): 984–93PubMedCrossRef Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004 Mar 15; 22(6): 984–93PubMedCrossRef
10.
Zurück zum Zitat Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003 Jul; 39(2): 60–7PubMedCrossRef Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003 Jul; 39(2): 60–7PubMedCrossRef
11.
Zurück zum Zitat Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17(3): 832–45PubMed Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17(3): 832–45PubMed
12.
Zurück zum Zitat Wiener MD, Boyko OB, Friedman HS, et al. False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR Am J Neuroradiol 1990; 11(6): 1100–3PubMed Wiener MD, Boyko OB, Friedman HS, et al. False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR Am J Neuroradiol 1990; 11(6): 1100–3PubMed
13.
Zurück zum Zitat Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005 Mar 10; 352(10): 978–86PubMedCrossRef Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005 Mar 10; 352(10): 978–86PubMedCrossRef
14.
Zurück zum Zitat Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 2008 Jun; 50(6): 1169–75PubMedCrossRef Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 2008 Jun; 50(6): 1169–75PubMedCrossRef
15.
Zurück zum Zitat Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006 Sep 1; 24(25): 4202–8PubMedCrossRef Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006 Sep 1; 24(25): 4202–8PubMedCrossRef
16.
Zurück zum Zitat Gottardo NG, Gajjar A. Current therapy for medulloblastoma. Curr Treat Options Neurol 2006; 8(4): 319–34PubMedCrossRef Gottardo NG, Gajjar A. Current therapy for medulloblastoma. Curr Treat Options Neurol 2006; 8(4): 319–34PubMedCrossRef
17.
Zurück zum Zitat Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006 Oct; 7(10): 813–20PubMedCrossRef Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006 Oct; 7(10): 813–20PubMedCrossRef
18.
Zurück zum Zitat Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005 Oct 1; 23(28): 7152–60PubMedCrossRef Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005 Oct 1; 23(28): 7152–60PubMedCrossRef
19.
Zurück zum Zitat Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol 2005 Oct 20; 23(30): 7621–31PubMedCrossRef Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol 2005 Oct 20; 23(30): 7621–31PubMedCrossRef
20.
Zurück zum Zitat Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 1994 Aug; 12(8): 1607–15PubMed Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 1994 Aug; 12(8): 1607–15PubMed
21.
Zurück zum Zitat Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1999 Apr; 1(2): 152–61PubMed Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1999 Apr; 1(2): 152–61PubMed
22.
Zurück zum Zitat Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993 Jun 17; 328(24): 1725–31PubMedCrossRef Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993 Jun 17; 328(24): 1725–31PubMedCrossRef
23.
Zurück zum Zitat Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6: 573–80PubMedCrossRef Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6: 573–80PubMedCrossRef
24.
Zurück zum Zitat Grotzer MA, von Hoff K, von Bueren AO, et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT’91: implications for investigating childhood medulloblastoma. Klin Padiatr 2007 Nov–Dec; 219(6): 312–7PubMedCrossRef Grotzer MA, von Hoff K, von Bueren AO, et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT’91: implications for investigating childhood medulloblastoma. Klin Padiatr 2007 Nov–Dec; 219(6): 312–7PubMedCrossRef
25.
Zurück zum Zitat Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005 Nov 1; 23(31): 7951–7PubMedCrossRef Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005 Nov 1; 23(31): 7951–7PubMedCrossRef
26.
Zurück zum Zitat Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004 May; 63(5): 441–9PubMed Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004 May; 63(5): 441–9PubMed
27.
Zurück zum Zitat Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994; 91(26): 12867–71PubMedCrossRef Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994; 91(26): 12867–71PubMedCrossRef
28.
Zurück zum Zitat Korshunov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas: the effect of apoptotic index, TrkC, and C-myc expression. J Neurooncol 2002; 58(3): 271–9PubMedCrossRef Korshunov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas: the effect of apoptotic index, TrkC, and C-myc expression. J Neurooncol 2002; 58(3): 271–9PubMedCrossRef
29.
Zurück zum Zitat Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma: a fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 2002 May; 126(5): 540–4PubMed Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma: a fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 2002 May; 126(5): 540–4PubMed
30.
Zurück zum Zitat Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001 Aug; 7(8): 2425–33PubMed Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001 Aug; 7(8): 2425–33PubMed
31.
Zurück zum Zitat Hernan R, Fasheh R, Calabrese C, et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003 Jan 1; 63(1): 140–8PubMed Hernan R, Fasheh R, Calabrese C, et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003 Jan 1; 63(1): 140–8PubMed
32.
Zurück zum Zitat Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998 Jul; 16(7): 2478–85PubMed Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998 Jul; 16(7): 2478–85PubMed
33.
Zurück zum Zitat Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 2006; 42(17): 2996–3003PubMedCrossRef Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 2006; 42(17): 2996–3003PubMedCrossRef
34.
Zurück zum Zitat Ellison DW, Clifford SC, Gajjar A, et al. What’s new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003; 7(2): 53–66PubMedCrossRef Ellison DW, Clifford SC, Gajjar A, et al. What’s new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003; 7(2): 53–66PubMedCrossRef
35.
36.
Zurück zum Zitat Gilbertson RJ, Gutmann DH. Tumorigenesis in the brain: location, location, location. Cancer Res 2007 Jun 15; 67(12): 5579–82PubMedCrossRef Gilbertson RJ, Gutmann DH. Tumorigenesis in the brain: location, location, location. Cancer Res 2007 Jun 15; 67(12): 5579–82PubMedCrossRef
37.
Zurück zum Zitat Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004 Apr; 5(4): 209–18PubMedCrossRef Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004 Apr; 5(4): 209–18PubMedCrossRef
38.
Zurück zum Zitat Gilbertson RJ, Gajjar A. Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol 2005 Dec; 75(3): 273–8PubMedCrossRef Gilbertson RJ, Gajjar A. Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol 2005 Dec; 75(3): 273–8PubMedCrossRef
39.
Zurück zum Zitat Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3(32): 1–16 Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3(32): 1–16
40.
Zurück zum Zitat Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996 Jun 14; 85(6): 841–51PubMedCrossRef Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996 Jun 14; 85(6): 841–51PubMedCrossRef
41.
Zurück zum Zitat Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996 Jun 14; 272(5268): 1668–71PubMedCrossRef Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996 Jun 14; 272(5268): 1668–71PubMedCrossRef
42.
Zurück zum Zitat Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic hedgehog. Neuron 1999 Jan; 22(1): 103–14PubMedCrossRef Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic hedgehog. Neuron 1999 Jan; 22(1): 103–14PubMedCrossRef
43.
Zurück zum Zitat Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385–428PubMedCrossRef Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385–428PubMedCrossRef
44.
Zurück zum Zitat Lee Y, Miller HL, Jensen P, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003 Sep 1; 63(17): 5428–37PubMed Lee Y, Miller HL, Jensen P, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003 Sep 1; 63(17): 5428–37PubMed
45.
Zurück zum Zitat Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997 Jun 1; 57(11): 2085–8PubMed Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997 Jun 1; 57(11): 2085–8PubMed
46.
Zurück zum Zitat Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000 Jan; 27(1): 44–51PubMedCrossRef Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000 Jan; 27(1): 44–51PubMedCrossRef
47.
Zurück zum Zitat Zurawel RH, Allen C, Wechsler-Reya R, et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000 May; 28(1): 77–81PubMedCrossRef Zurawel RH, Allen C, Wechsler-Reya R, et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000 May; 28(1): 77–81PubMedCrossRef
48.
Zurück zum Zitat Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005 Jul 1; 11(13): 4733–40PubMedCrossRef Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005 Jul 1; 11(13): 4733–40PubMedCrossRef
49.
Zurück zum Zitat Di Marcotullio L, Ferretti E, De Smaele E, et al. REN(KCTD11) is a suppressor of hedgehog signalling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A 2004 Jul 20; 101(29): 10833–8PubMedCrossRef Di Marcotullio L, Ferretti E, De Smaele E, et al. REN(KCTD11) is a suppressor of hedgehog signalling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A 2004 Jul 20; 101(29): 10833–8PubMedCrossRef
50.
Zurück zum Zitat De Smaele E, Di Marcotullio L, Ferretti E, et al. Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway. Cell Cycle 2004 Oct; 3(10): 1263–6PubMedCrossRef De Smaele E, Di Marcotullio L, Ferretti E, et al. Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway. Cell Cycle 2004 Oct; 3(10): 1263–6PubMedCrossRef
51.
Zurück zum Zitat Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007 Sep; 194(3): 459–74PubMedCrossRef Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007 Sep; 194(3): 459–74PubMedCrossRef
52.
Zurück zum Zitat Shih Ie M, Wang TL. Notch signalling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007 Mar 1; 67(5): 1879–82PubMedCrossRef Shih Ie M, Wang TL. Notch signalling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007 Mar 1; 67(5): 1879–82PubMedCrossRef
53.
Zurück zum Zitat Lissemore JL, Starmer WT. Phylogenetic analysis of vertebrate and invertebrate Delta/Serrate/LAG-2 (DSL) proteins. Mol Phylogenet Evol 1999 Mar; 11(2): 308–19PubMedCrossRef Lissemore JL, Starmer WT. Phylogenetic analysis of vertebrate and invertebrate Delta/Serrate/LAG-2 (DSL) proteins. Mol Phylogenet Evol 1999 Mar; 11(2): 308–19PubMedCrossRef
54.
Zurück zum Zitat Singh SK, Clarke ID, Hide T, et al. Cancer stem cells in nervous system tumors. Oncogene 2004 Sep 20; 23(43): 7267–73PubMedCrossRef Singh SK, Clarke ID, Hide T, et al. Cancer stem cells in nervous system tumors. Oncogene 2004 Sep 20; 23(43): 7267–73PubMedCrossRef
55.
Zurück zum Zitat Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 Sep 15; 63(18): 5821–8PubMed Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 Sep 15; 63(18): 5821–8PubMed
56.
Zurück zum Zitat Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004 Nov 18; 432(7015): 396–401PubMedCrossRef Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004 Nov 18; 432(7015): 396–401PubMedCrossRef
57.
Zurück zum Zitat Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006 Aug 1; 66(15): 7445–52PubMedCrossRef Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006 Aug 1; 66(15): 7445–52PubMedCrossRef
58.
Zurück zum Zitat Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000 Apr; 59(4): 333–7PubMed Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000 Apr; 59(4): 333–7PubMed
59.
Zurück zum Zitat Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006 Nov; 5(22): 2666–70PubMedCrossRef Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006 Nov; 5(22): 2666–70PubMedCrossRef
60.
Zurück zum Zitat Salaroli R, Di Tomaso T, Ronchi A, et al. Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin? J Neurooncol 2008; 90(3): 243–51PubMedCrossRef Salaroli R, Di Tomaso T, Ronchi A, et al. Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin? J Neurooncol 2008; 90(3): 243–51PubMedCrossRef
61.
Zurück zum Zitat Kratz JE, Stearns D, Huso DL, et al. Expression of stabilized beta-catenin in differentiated neurons of transgenic mice does not result in tumor formation. BMC Cancer 2002 Dec 2; 233: 1–9 Kratz JE, Stearns D, Huso DL, et al. Expression of stabilized beta-catenin in differentiated neurons of transgenic mice does not result in tumor formation. BMC Cancer 2002 Dec 2; 233: 1–9
62.
Zurück zum Zitat Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997 Aug 1; 57(15): 3272–80PubMed Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997 Aug 1; 57(15): 3272–80PubMed
63.
Zurück zum Zitat Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001 Sep 1; 85(5): 705–12PubMedCrossRef Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001 Sep 1; 85(5): 705–12PubMedCrossRef
64.
Zurück zum Zitat Slongo ML, Molena B, Brunati AM, et al. Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro Oncol 2007 Oct; 9(4): 384–92PubMedCrossRef Slongo ML, Molena B, Brunati AM, et al. Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro Oncol 2007 Oct; 9(4): 384–92PubMedCrossRef
65.
Zurück zum Zitat Patti R, Reddy CD, Geoerger B, et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuro-ectodermal tumor/medulloblastoma. Int J Oncol 2000 Mar; 16(3): 577–84PubMed Patti R, Reddy CD, Geoerger B, et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuro-ectodermal tumor/medulloblastoma. Int J Oncol 2000 Mar; 16(3): 577–84PubMed
66.
Zurück zum Zitat Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000 Sep 15; 275(37): 28341–4PubMedCrossRef Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000 Sep 15; 275(37): 28341–4PubMedCrossRef
67.
Zurück zum Zitat Li Y, Guessous F, Johnson EB, et al. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 2008 Feb; 88(2): 98–111PubMedCrossRef Li Y, Guessous F, Johnson EB, et al. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 2008 Feb; 88(2): 98–111PubMedCrossRef
68.
Zurück zum Zitat Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005 Oct 15; 65(20): 9355–62PubMedCrossRef Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005 Oct 15; 65(20): 9355–62PubMedCrossRef
69.
Zurück zum Zitat Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001 Jan 15; 61(2): 513–6PubMed Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001 Jan 15; 61(2): 513–6PubMed
70.
Zurück zum Zitat Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signalling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004 Nov 1; 64(21): 7794–800PubMedCrossRef Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signalling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004 Nov 1; 64(21): 7794–800PubMedCrossRef
71.
Zurück zum Zitat Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997 Aug 22; 277(5329): 1109–13PubMedCrossRef Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997 Aug 22; 277(5329): 1109–13PubMedCrossRef
72.
Zurück zum Zitat Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008 Mar 15; 68(6): 1768–76PubMedCrossRef Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008 Mar 15; 68(6): 1768–76PubMedCrossRef
73.
Zurück zum Zitat Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 2005 Jun 15; 65(12): 4975–8PubMedCrossRef Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 2005 Jun 15; 65(12): 4975–8PubMedCrossRef
74.
Zurück zum Zitat Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 2004 Sep; 6(3): 229–40PubMedCrossRef Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 2004 Sep; 6(3): 229–40PubMedCrossRef
75.
Zurück zum Zitat Matthay KK, Villablanca JG, Seeger RC, et al., on behalf of the Children’s Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med 1999 Oct 14; 341(16): 1165–73PubMedCrossRef Matthay KK, Villablanca JG, Seeger RC, et al., on behalf of the Children’s Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med 1999 Oct 14; 341(16): 1165–73PubMedCrossRef
76.
Zurück zum Zitat Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008 Mar 1; 111(5): 2505–15PubMedCrossRef Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008 Mar 1; 111(5): 2505–15PubMedCrossRef
77.
Zurück zum Zitat Chang Q, Chen Z, You J, et al. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol 2007 Sep; 84(3): 263–7PubMedCrossRef Chang Q, Chen Z, You J, et al. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol 2007 Sep; 84(3): 263–7PubMedCrossRef
78.
Zurück zum Zitat Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003 Aug; 9(8): 1033–8PubMedCrossRef Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003 Aug; 9(8): 1033–8PubMedCrossRef
79.
Zurück zum Zitat Damodar Reddy C, Guttapalli A, Adamson PC, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett 2006 Jan 18; 231(2): 262–9PubMedCrossRef Damodar Reddy C, Guttapalli A, Adamson PC, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett 2006 Jan 18; 231(2): 262–9PubMedCrossRef
80.
Zurück zum Zitat Spiller SE, Ditzler SH, Pullar BJ, et al. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008 Apr; 87(2): 133–41PubMedCrossRef Spiller SE, Ditzler SH, Pullar BJ, et al. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008 Apr; 87(2): 133–41PubMedCrossRef
81.
Zurück zum Zitat Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer’s disease: a medicinal chemistry perspective. Curr Top Med Chem 2008; 8(1): 38–46PubMedCrossRef Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer’s disease: a medicinal chemistry perspective. Curr Top Med Chem 2008; 8(1): 38–46PubMedCrossRef
82.
Zurück zum Zitat Evin G. Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer’s treatment. Expert Rev Neurother 2008 Nov; 8(11): 1611–3PubMedCrossRef Evin G. Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer’s treatment. Expert Rev Neurother 2008 Nov; 8(11): 1611–3PubMedCrossRef
83.
Zurück zum Zitat Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002 Aug 30; 297(5586): 1559–61PubMedCrossRef Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002 Aug 30; 297(5586): 1559–61PubMedCrossRef
84.
Zurück zum Zitat Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361(12): 1173–8PubMedCrossRef Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361(12): 1173–8PubMedCrossRef
85.
Zurück zum Zitat Emanuel SL, Hughes TV, Adams M, et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline panErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 2008 Feb; 73(2): 338–48PubMedCrossRef Emanuel SL, Hughes TV, Adams M, et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline panErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 2008 Feb; 73(2): 338–48PubMedCrossRef
86.
Zurück zum Zitat Easwaran V, Pishvaian M, Salimuddin, et al. Cross-regulation of beta-catenin-LEF/TCF and retinoid signalling pathways. Curr Biol 1999 Dec 2; 9(23): 1415–8PubMedCrossRef Easwaran V, Pishvaian M, Salimuddin, et al. Cross-regulation of beta-catenin-LEF/TCF and retinoid signalling pathways. Curr Biol 1999 Dec 2; 9(23): 1415–8PubMedCrossRef
87.
Zurück zum Zitat Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5(7): 399–408PubMedCrossRef Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5(7): 399–408PubMedCrossRef
88.
Zurück zum Zitat Duffner P. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10(6): 293–310PubMedCrossRef Duffner P. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10(6): 293–310PubMedCrossRef
89.
Zurück zum Zitat Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990; 72(4): 572–82PubMedCrossRef Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990; 72(4): 572–82PubMedCrossRef
90.
Zurück zum Zitat Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26(4): 464–9PubMed Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26(4): 464–9PubMed
91.
Zurück zum Zitat Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003 Apr 15; 21(8): 1581–91PubMedCrossRef Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003 Apr 15; 21(8): 1581–91PubMedCrossRef
92.
Zurück zum Zitat Packer RJ, Goldwein JW, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 1999; 17: 2127–36PubMed Packer RJ, Goldwein JW, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 1999; 17: 2127–36PubMed
93.
Zurück zum Zitat Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 1989; 71(6): 820–5PubMedCrossRef Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 1989; 71(6): 820–5PubMedCrossRef
94.
Zurück zum Zitat Mosijczuk AD, Nigro MA, Thomas PRM, et al. Preradiation chemotherapy in advanced medulloblastoma: a Pediatric Oncology Group pilot study. Cancer 1993; 72(9): 2755–62PubMedCrossRef Mosijczuk AD, Nigro MA, Thomas PRM, et al. Preradiation chemotherapy in advanced medulloblastoma: a Pediatric Oncology Group pilot study. Cancer 1993; 72(9): 2755–62PubMedCrossRef
95.
Zurück zum Zitat Kortmann R-D, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’ 91. Int J Radiat Oncol Biol Phys 2000; 46(2): 269–79PubMedCrossRef Kortmann R-D, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’ 91. Int J Radiat Oncol Biol Phys 2000; 46(2): 269–79PubMedCrossRef
96.
Zurück zum Zitat Lampkin BC, Mauer AM, McBride BH. Response to medulloblastoma to vincristine sulfate: a case report. Pediatrics 1967 May 1; 39(5): 761–3PubMed Lampkin BC, Mauer AM, McBride BH. Response to medulloblastoma to vincristine sulfate: a case report. Pediatrics 1967 May 1; 39(5): 761–3PubMed
97.
Zurück zum Zitat Jackson Jr D, Sethi V, Spurr C, et al. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981; 41: 1466–8PubMed Jackson Jr D, Sethi V, Spurr C, et al. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981; 41: 1466–8PubMed
98.
Zurück zum Zitat Kellie SJ, Barbaric D, Koopmans P, et al. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing. Cancer 2002; 94(6): 1815–20PubMedCrossRef Kellie SJ, Barbaric D, Koopmans P, et al. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing. Cancer 2002; 94(6): 1815–20PubMedCrossRef
99.
Zurück zum Zitat Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990; 28: 823–8PubMedCrossRef Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990; 28: 823–8PubMedCrossRef
100.
Zurück zum Zitat Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981; 55: 749–56PubMedCrossRef Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981; 55: 749–56PubMedCrossRef
101.
Zurück zum Zitat Moghrabi A, Fuchs H, Brown M, et al. Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Med Pediatr Oncol 1995; 25(3): 190–6PubMedCrossRef Moghrabi A, Fuchs H, Brown M, et al. Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Med Pediatr Oncol 1995; 25(3): 190–6PubMedCrossRef
102.
Zurück zum Zitat Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 2007; 110(7): 1542–50PubMedCrossRef Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 2007; 110(7): 1542–50PubMedCrossRef
103.
Zurück zum Zitat Packer RJ, Sutton LN, Elterman RD, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994; 81: 690–8PubMedCrossRef Packer RJ, Sutton LN, Elterman RD, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994; 81: 690–8PubMedCrossRef
104.
Zurück zum Zitat Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987 Mar 1; 5(3): 459–63PubMed Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987 Mar 1; 5(3): 459–63PubMed
105.
Zurück zum Zitat Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors: a Children’s Cancer Study Group Phase II trial. Cancer 1990; 66(12): 2465–9PubMedCrossRef Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors: a Children’s Cancer Study Group Phase II trial. Cancer 1990; 66(12): 2465–9PubMedCrossRef
106.
Zurück zum Zitat Mastrangelo R, Lasorella A, Riccardi R, et al. Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an “up-front” study. Med Ped Oncol 1995; 24(3): 188–96CrossRef Mastrangelo R, Lasorella A, Riccardi R, et al. Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an “up-front” study. Med Ped Oncol 1995; 24(3): 188–96CrossRef
107.
Zurück zum Zitat Bergman I, Jakacki RI, Heller G, et al. Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. Med Pediatr Oncol 1997 Dec; 29(6): 563–7PubMedCrossRef Bergman I, Jakacki RI, Heller G, et al. Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. Med Pediatr Oncol 1997 Dec; 29(6): 563–7PubMedCrossRef
108.
Zurück zum Zitat Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000; 35(2): 75–93PubMedCrossRef Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000; 35(2): 75–93PubMedCrossRef
109.
Zurück zum Zitat Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors. Cancer 2006; 107(9): 2291–7PubMedCrossRef Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors. Cancer 2006; 107(9): 2291–7PubMedCrossRef
110.
Zurück zum Zitat Fossati-Bellani F, Tesoro-Tess JD, Ballerini E. Medulloblastoma (MBL): evaluation of the effectiveness of pre-radiation (RT) chemotherapy (CT) [abstract]. Med Ped Oncol 1990; 18: 361CrossRef Fossati-Bellani F, Tesoro-Tess JD, Ballerini E. Medulloblastoma (MBL): evaluation of the effectiveness of pre-radiation (RT) chemotherapy (CT) [abstract]. Med Ped Oncol 1990; 18: 361CrossRef
111.
Zurück zum Zitat Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol 1988 Apr 1; 6(4): 649–53PubMed Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol 1988 Apr 1; 6(4): 649–53PubMed
112.
Zurück zum Zitat Lashford L, Campbell R, Gattamaneni H, et al. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 1996 Mar1; 74(3): 219–23PubMedCrossRef Lashford L, Campbell R, Gattamaneni H, et al. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 1996 Mar1; 74(3): 219–23PubMedCrossRef
113.
Zurück zum Zitat Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004 Dec 15; 22(24): 4881–7PubMedCrossRef Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004 Dec 15; 22(24): 4881–7PubMedCrossRef
114.
Zurück zum Zitat Mason W, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998 Jan 1; 16(1): 210–21PubMed Mason W, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998 Jan 1; 16(1): 210–21PubMed
115.
Zurück zum Zitat Kadota RP, Stewart CF, Horn M, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors: a Pediatric Oncology Group phase II study. J Neurooncol 1999; 43(1): 43–7PubMedCrossRef Kadota RP, Stewart CF, Horn M, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors: a Pediatric Oncology Group phase II study. J Neurooncol 1999; 43(1): 43–7PubMedCrossRef
116.
Zurück zum Zitat Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78(3): 527–31PubMedCrossRef Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78(3): 527–31PubMedCrossRef
117.
Zurück zum Zitat Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001 May 15; 19(10): 2696–704PubMed Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001 May 15; 19(10): 2696–704PubMed
118.
Zurück zum Zitat Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004 Aug 15; 22(16): 3357–65PubMedCrossRef Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004 Aug 15; 22(16): 3357–65PubMedCrossRef
119.
Zurück zum Zitat Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990 Feb 1; 8(2): 330–6PubMed Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990 Feb 1; 8(2): 330–6PubMed
120.
Zurück zum Zitat Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14(6): 1922–7PubMed Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14(6): 1922–7PubMed
121.
Zurück zum Zitat Moghrabi A, Hershon L, Rousseau P, et al. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631 [abstract]. Neuro-oncology 2008; 10(3): 476. 13th Annual ISPNO Meeting; 29 Jun–2 Jul 2008; Chicago (IL) Moghrabi A, Hershon L, Rousseau P, et al. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631 [abstract]. Neuro-oncology 2008; 10(3): 476. 13th Annual ISPNO Meeting; 29 Jun–2 Jul 2008; Chicago (IL)
122.
Zurück zum Zitat Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neuro-Oncol 1996; 27: 87–98CrossRef Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neuro-Oncol 1996; 27: 87–98CrossRef
123.
Zurück zum Zitat Mahoney Jr DH, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996; 14: 382–8PubMed Mahoney Jr DH, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996; 14: 382–8PubMed
124.
Zurück zum Zitat Graham ML, Herndon 2nd JE, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15(5): 1814–23PubMed Graham ML, Herndon 2nd JE, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15(5): 1814–23PubMed
125.
Zurück zum Zitat Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486–93PubMed Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486–93PubMed
126.
Zurück zum Zitat Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998; 16(1): 222–8PubMed Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998; 16(1): 222–8PubMed
127.
Zurück zum Zitat Grill J, Renaux VK, Bulteau C, et al. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999; 45(1): 137–45PubMedCrossRef Grill J, Renaux VK, Bulteau C, et al. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999; 45(1): 137–45PubMedCrossRef
128.
Zurück zum Zitat Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19: 480–7PubMed Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19: 480–7PubMed
129.
Zurück zum Zitat Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy cranio-spinal radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53(3): 543–7PubMedCrossRef Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy cranio-spinal radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53(3): 543–7PubMedCrossRef
130.
Zurück zum Zitat Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2003 Oct 1; 88(10): 4731–9PubMedCrossRef Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2003 Oct 1; 88(10): 4731–9PubMedCrossRef
131.
Zurück zum Zitat Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52(3): 599–605PubMedCrossRef Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52(3): 599–605PubMedCrossRef
132.
Zurück zum Zitat Fukunaga-Johnson N, Sandler HM, Marsh R, et al. The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int J Radiat Oncol Biol Phys 1998; 41(1): 77–82PubMedCrossRef Fukunaga-Johnson N, Sandler HM, Marsh R, et al. The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int J Radiat Oncol Biol Phys 1998; 41(1): 77–82PubMedCrossRef
133.
Zurück zum Zitat Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23(34): 8588–96PubMedCrossRef Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23(34): 8588–96PubMedCrossRef
134.
Zurück zum Zitat Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004 Aug 15; 10(16): 5482–93PubMedCrossRef Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004 Aug 15; 10(16): 5482–93PubMedCrossRef
Metadaten
Titel
Childhood Medulloblastoma
Current Status of Biology and Treatment
verfasst von
Dr Laura J. Klesse
Daniel C. Bowers
Publikationsdatum
01.04.2010
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 4/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11530140-000000000-00000

Weitere Artikel der Ausgabe 4/2010

CNS Drugs 4/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.